PURPOSE: The tyrosine kinase inhibitors sorafenib and sunitinib have efficacy in several types of cancer. Recent studies indicate that these agents affect the immune system. The way it affects the immune response to influenza vaccination is unknown. The aim of this study was to elucidate the specific immune response to seasonal flu vaccination in cancer patients treated with sunitinib or sorafenib. PATIENTS AND METHODS: Sunitinib- or sorafenib-treated cancer patients were vaccinated against seasonal influenza with an inactivated vaccine. Healthy controls and patients with metastatic renal cell cancer (mRCC) without systemic treatment (nontreated mRCC controls) were included for comparison. Antibody responses were measured at baseline, day 8, and day 22 by a standard hemagglutination inhibition assay and cellular T-cell responses at baseline and day 8 by proliferation assay and secretion of cytokines. RESULTS: Forty subjects were enrolled: 16 patients treated with sunitinib, 6 patients with sorafenib, 7 nontreated mRCC controls, and 11 healthy controls. All patients treated with sunitinib and sorafenib developed seroprotection rates comparable with controls. Functional T-cell reactivity was observed in all groups, except for patients treated with sorafenib who showed a decreased proliferation rate and IFN-γ/IL-2 production and increased IL-10 compared with healthy controls. CONCLUSION: We conclude that influenza vaccination should be recommended to cancer patients treated with sunitinib or sorafenib.
PURPOSE: The tyrosine kinase inhibitors sorafenib and sunitinib have efficacy in several types of cancer. Recent studies indicate that these agents affect the immune system. The way it affects the immune response to influenza vaccination is unknown. The aim of this study was to elucidate the specific immune response to seasonal flu vaccination in cancerpatients treated with sunitinib or sorafenib. PATIENTS AND METHODS: Sunitinib- or sorafenib-treated cancerpatients were vaccinated against seasonal influenza with an inactivated vaccine. Healthy controls and patients with metastatic renal cell cancer (mRCC) without systemic treatment (nontreated mRCC controls) were included for comparison. Antibody responses were measured at baseline, day 8, and day 22 by a standard hemagglutination inhibition assay and cellular T-cell responses at baseline and day 8 by proliferation assay and secretion of cytokines. RESULTS: Forty subjects were enrolled: 16 patients treated with sunitinib, 6 patients with sorafenib, 7 nontreated mRCC controls, and 11 healthy controls. All patients treated with sunitinib and sorafenib developed seroprotection rates comparable with controls. Functional T-cell reactivity was observed in all groups, except for patients treated with sorafenib who showed a decreased proliferation rate and IFN-γ/IL-2 production and increased IL-10 compared with healthy controls. CONCLUSION: We conclude that influenza vaccination should be recommended to cancerpatients treated with sunitinib or sorafenib.
Authors: Hetty Prinsen; Hanneke W M van Laarhoven; Jeanette M Pots; Tjitske Duiveman-de Boer; Sasja F Mulder; Carla M L van Herpen; Joannes F M Jacobs; Jan Willem H Leer; Gijs Bleijenberg; Foekje F Stelma; Ruurd Torensma; I Jolanda M de Vries Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Dai Liu; Xiaoqiang Qi; Yariswamy Manjunath; Eric T Kimchi; Lixin Ma; Jussuf T Kaifi; Kevin F Staveley-O'Carroll; Guangfu Li Journal: J Immunol Res Ther Date: 2018-06-08
Authors: C T Rieger; B Liss; S Mellinghoff; D Buchheidt; O A Cornely; G Egerer; W J Heinz; M Hentrich; G Maschmeyer; K Mayer; M Sandherr; G Silling; A Ullmann; M J G T Vehreschild; M von Lilienfeld-Toal; H H Wolf; N Lehners Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Hetty Prinsen; I Jolanda M de Vries; Ruurd Torensma; Jeanette M Pots; Sasja F Mulder; Carla M L van Herpen; Lammy D Elving; Gijs Bleijenberg; Foekje F Stelma; Hanneke W M van Laarhoven Journal: BMC Immunol Date: 2012-12-17 Impact factor: 3.615